Larvol Delta - A-Platform-Study-of-Novel-Immunotherapy-Combinations-as-FirstLine-Treatment-in-Participants-With-PDL1-Positive-RecurrentMetastatic-Squamous-Cell-Carcinoma-of-the-Head-and-Neck-GALAXIES-HampN202

Jemperli (dostarlimab-gxly) - GSK

nelistotug (GSK6097608) - GSK

belrestotug (EOS-448) - GSK, Concentra Biosciences

http://clinicaltrials.gov/ct2/show/NCT06062420

Apr 10, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next